drugset / Trial / NCT01599936

Open Label Clinical Trial of Anascorp® in Pediatric Patients With Scorpion Sting Envenomation

NCT01599936 ↗

NaSingle-groupOpen-labelTreatment

Summary

There is no FDA approved therapy for the treatment of scorpion envenomation. Centruroides scorpion envenomation produces a pattern of neurotoxicity with a spectrum of severity ranging from trivial to life threatening. Patients stung by Centruroides scorpions develop a clinical syndrome which may require sedation with benzodiazepines and observation for 6 to 28 hours of intensive care monitoring. A safe therapy is necessary to halt the progression of symptoms early in the clinical course while avoiding the clinical deterioration that can occur en route to a tertiary facility. Alacramyn® is anticipated to be safer and more effective than the present standard of care, midazolam, and faster-acting thus eliminating the need to transport most rural patients and reducing hospitalization time.

Timeline

Start
2004-04
Primary completion
2006-10
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Anascorp Unknown — Intravenous

Indications